Mass Spectrometry Reviews最新文献

Liquid chromatography-mass spectrometry (LC–MS) is a powerful technique for the detection and quantification of methylated quaternary ammonium compounds (mQACs), such as acylcarnitines and methylated amino-acid-derived (betainized) compounds, in biological matrices. Due to their high polarity and permanent charge, mQACs present analytical challenges, particularly in achieving efficient chromatographic retention and resolution. Here, we focus on the application of hydrophilic interaction liquid chromatography combined with mass spectrometric (HILIC–MS), for the analysis of these compound classes in biological samples. We highlight practical considerations in their analysis, including their MS/MS fragmentation patterns and identification in positive electrospray mode (ESI)⁺, to support researchers working with mQACs in targeted or untargeted metabolomics studies.

In the 1980s, researchers discovered the remarkable ability of electrospray plumes to effectively ionize gas-phase molecules via secondary ionization. Around 20 years later-coinciding with the ambient mass spectrometry revolution-secondary electrospray ionization (SESI) and extractive electrospray ionization (EESI) coupled to mass spectrometry were revisited and further developed to analyze complex mixtures of gas and aerosol samples in real-time yet with high sensitivity. During the past two decades, these mass spectrometric techniques have been applied across a broad range of applications, such as the detection of illicit drugs, environmental aerosol analysis, and a series of metabolomic studies through the analysis of volatiles emitted from living organisms. This review offers a comprehensive overview of the progress of SESI and EESI applications since their emergence. Finally, we discuss the opportunities, challenges, along with future directions of SESI and EESI techniques.

Lipopolysaccharides (LPS) are complex molecules embedded in the outer membrane of Gram-negative bacteria. LPS are highly heterogeneous across species and strains, posing a significant analytical challenge. This review article explores recent advances in the identification and characterization of LPS, with a particular focus on the role of mass spectrometry (MS) techniques. The review highlights how MS, in conjunction with various separation methods and spanning different ionization techniques and dissociation modes, has enabled more precise and sensitive determination of LPS composition, with a focus on lipid A structure. Finally, emerging trends in MS applications for LPS research are discussed and its potential to provide deeper insights into the development of antibiotic resistance among pathogenic bacteria.

Cancer is the leading cause of death worldwide characterized by patient heterogeneity and complex tumor microenvironment. While the genomics-based testing has transformed modern medicine, the challenge of diverse clinical outcomes highlights unmet needs for precision oncology. As functional molecules regulating cellular processes, proteins hold great promise as biomarkers and drug targets. Mass spectrometry (MS)-based clinical proteomics has illuminated the molecular features of cancers and facilitated discovery of biomarkers or therapeutic targets, paving the way for innovative strategies that enhance the precision of personalized treatment. In this article, we introduced the tools and current achievements of MS-based proteomics, choice of discovery and targeted MS from discovery to validation phases, profiling sensitivity from bulk samples to single-cell level and tissue to liquid biopsy specimens, current regulatory landscape of MS-based protein laboratory-developed tests (LDTs). The challenges, success and future perspectives in translating research MS assay into clinical applications are also discussed. With well-designed validation studies to demonstrate clinical benefits and meet the regulatory requirements for both analytical and clinical performance, the future of MS-based assays is promising with numerous opportunities to improve cancer diagnosis, treatment, and monitoring.

Mass spectrometry-based proteomics is essential for advancing preventive and personalised medicine. Technological advancements have greatly increased both the number and sensitivity of spectra generated in a single experiment. Traditionally, spectra are identified using database search engines that depend on large and continuously expanding databases. This expansion enlarges the search space, posing challenges for controlling the false discovery rate in peptide identification. While many bioinformatic workflows employ rescoring algorithms as a post-processing step to manage false discoveries, preprocessing spectra offers a promising alternative. One such method, spectral quality assessment, classifies spectra as "high" quality (likely containing a peptide) or "low" quality (predominantly consisting of noise). This review provides a comprehensive perspective on spectral quality assessment, examining existing tools and their underlying principles. We discuss key considerations such as the definition of spectral quality, normalisation, the use of experimental training data, and future research in the field. By highlighting the potential of spectral quality assessment to improve peptide identification and reduce false discoveries, we aim to elaborate on its potential for the proteomics community.